Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seth P Lerner

Showing results (241-250 of 294) with videos related to

Pageof 30
Sort By:
Nature Reviews. Urology|September 11, 2021
Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshopElaine Chang, Andrea B Apolo, Rick Bangs, et al.
Urology|February 4, 2014
Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysisJamie C Messer, Shahrokh F Shariat, Colin P Dinney, et al.
The New England Journal of Medicine|November 26, 2024
Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder CancerSeth P Lerner, Catherine Tangen, Robert S Svatek, et al.
European Urology Focus|July 30, 2017
Distinct Lipidomic Landscapes Associated with Clinical Stages of Urothelial Cancer of the BladderDanthasinghe Waduge Badrajee Piyarathna, Thekkelnaycke M Rajendiran, Vasanta Putluri, et al.
European Urology|April 5, 2024
Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 TrialSumanta K Pal, Petros Grivas, Shilpa Gupta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2019
Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive TrialsMax Kates, Andres Matoso, Woonyoung Choi, et al.
European Urology Focus|September 3, 2019
Erratum to "Distinct Lipidomic Landscapes Associated with Clinical Stages of Urothelial Cancer of the Bladder" [Eur Urol Focus 2018;4:907-915]Danthasinghe Waduge Badrajee Piyarathna, Thekkelnaycke M Rajendiran, Vasanta Putluri, et al.
Carcinogenesis|July 9, 2019
DNA methylation patterns in bladder tumors of African American patients point to distinct alterations in xenobiotic metabolismVenkatrao Vantaku, Chandra Sekhar Amara, Danthasinghe Waduge Badrajee Piyarathna, et al.
Scientific Reports|January 20, 2017
Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive BehaviorAaron Mobley, Shizhen Zhang, Jolanta Bondaruk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2024
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell CarcinomaPedro Barata, Catherine Tangen, Melissa Plets, et al.
Pageof 30

Showing results (241-250 of 294) with videos related to

Sort By:
Pageof 30
Nature Reviews. Urology|September 11, 2021
Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshopElaine Chang, Andrea B Apolo, Rick Bangs, et al.
Urology|February 4, 2014
Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysisJamie C Messer, Shahrokh F Shariat, Colin P Dinney, et al.
The New England Journal of Medicine|November 26, 2024
Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder CancerSeth P Lerner, Catherine Tangen, Robert S Svatek, et al.
European Urology Focus|July 30, 2017
Distinct Lipidomic Landscapes Associated with Clinical Stages of Urothelial Cancer of the BladderDanthasinghe Waduge Badrajee Piyarathna, Thekkelnaycke M Rajendiran, Vasanta Putluri, et al.
European Urology|April 5, 2024
Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 TrialSumanta K Pal, Petros Grivas, Shilpa Gupta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2019
Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive TrialsMax Kates, Andres Matoso, Woonyoung Choi, et al.
European Urology Focus|September 3, 2019
Erratum to "Distinct Lipidomic Landscapes Associated with Clinical Stages of Urothelial Cancer of the Bladder" [Eur Urol Focus 2018;4:907-915]Danthasinghe Waduge Badrajee Piyarathna, Thekkelnaycke M Rajendiran, Vasanta Putluri, et al.
Carcinogenesis|July 9, 2019
DNA methylation patterns in bladder tumors of African American patients point to distinct alterations in xenobiotic metabolismVenkatrao Vantaku, Chandra Sekhar Amara, Danthasinghe Waduge Badrajee Piyarathna, et al.
Scientific Reports|January 20, 2017
Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive BehaviorAaron Mobley, Shizhen Zhang, Jolanta Bondaruk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2024
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell CarcinomaPedro Barata, Catherine Tangen, Melissa Plets, et al.
Pageof 30